Summary
Johnson & Johnson, through its Janssen Pharmaceutical Companies, announced the significant acquisition of all rights to the investigational compound bermekimab on December 30, 2019. This transaction, valued at $750 million, bolsters Janssen's dermatology pipeline with a compound targeting multiple dermatological indications. The acquisition includes certain employees from XBiotech Inc., indicating a strategic move to integrate talent and expertise. Janssen Research & Development, LLC will spearhead the further development of bermekimab, signaling a commitment to advancing this promising asset.
Key Highlights
- 1Janssen Pharmaceutical Companies acquired all rights to investigational compound bermekimab.
- 2The acquisition cost was $750 million.
- 3Bermekimab is intended for multiple dermatological indications.
- 4Certain employees from XBiotech Inc. were also acquired.
- 5Janssen Research & Development, LLC will be responsible for developing bermekimab.
- 6Potential for additional payments to XBiotech Inc. if bermekimab is pursued for non-dermatological indications.
- 7The acquisition represents a strategic investment in the dermatology sector.
Frequently Asked Questions
Bermekimab is an investigational compound with potential applications in treating various dermatological conditions. It is now owned by Johnson & Johnson's Janssen Pharmaceutical Companies.
The acquisition aims to strengthen Johnson & Johnson's dermatology portfolio by adding a promising investigational compound. This move is a strategic investment to advance treatments for skin diseases.
XBiotech Inc. may receive additional payments if Janssen decides to develop and commercialize bermekimab for indications outside of dermatology, upon receiving certain commercialization authorizations.
Janssen Research & Development, LLC, a part of Johnson & Johnson, will be responsible for the further development of bermekimab.